Please login to the form below

Not currently logged in
Email:
Password:

Bone Therapeutics strengthens board with new chairman

Jean Stéphenne joins the cell therapy company from TiGenix

Belgian biotechnology company Bone Therapeutics has appointed Jean Stéphenne as its new chairman of the board of directors, succeeding Steve Swinson in the process.

Stéphenne’s career history has seen him serve in senior leadership roles at several biotechnology and pharmaceutical companies, most recently as chairman of TiGenix.

He has also been a member of the corporate executive team for GlaxoSmithKline and chief executive officer of GSK Biologicals (now GSK Vaccines).

Thomas Lienard, chief executive officer of Bone Therapeutics, said: “Stéphenne has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector.

“He will be a valuable addition to an already strong board as we advance our allogeneic cell therapy platform through clinical studies.”

26th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics